Aurion Biotech, Inc. (AURN)
| Market Cap | n/a |
| Revenue (ttm) | 657,000 |
| Net Income | -59.92M |
| EPS | n/a |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About AURN
Aurion Biotech is a clinical-stage biotechnology company committed to developing and commercializing disease-modifying, regenerative therapies to restore vision to millions of patients worldwide. We are advancing a single administration, allogeneic cell therapy to treat vision loss due to corneal endothelial diseases. In Japan, our first-generation cell therapy product, HCEC-1, received regulatory and reimbursement approval, and launched commercially in September 2024 under the marketed name Vyznova. Our next-generation product candidate, AURN0... [Read more]
Financial Performance
Financial StatementsNews
Aurion Biotech to Highlight Momentum Across Upcoming Eye Bank and Ophthalmology Meetings in June
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)-- #AECOS2026--Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision, today ann...
Aurion Biotech to Give Oral Presentation on Regenerative Cell Therapy for Corneal Endothelial Disease at ASGCT 2026
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)-- #ASGCT--Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working to...
Aurion Biotech Doses First Patients in ASTRA Phase 3 Study, Evaluating AURN001 in Patients with Corneal Edema Secondary to Corneal Endothelial Dysfunction
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)-- #AurionBiotech--Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and wo...
Aurion Biotech Appoints World Renowned Cornea Surgeon Marjan Farid, M.D., to Chair Medical Advisory Board
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)-- #AurionBiotech--Aurion Biotech, Inc. (“Aurion”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working to...
Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)-- #AAO2025--Aurion Biotech, a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today announced...
Aurion Biotech Expands Leadership Team, Promoting Andrew Torres, Ph.D., to Chief Manufacturing Officer and Sterling Chung to Chief Regulatory & Quality Officer
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)-- #Biotech--Aurion Biotech, a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today announced...
Aurion Biotech Appoints Edward J. Holland, M.D.
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, a clinical-stage regenerative medicine company whose mission is to restore vision to millions of patients, today announced the appo...
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
GENEVA--(BUSINESS WIRE)--Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease.
Vision loss biotech Aurion Biotech files for a $100 million IPO
Aurion Biotech, a commercial-stage biotech developing regenerative cell therapies for eye diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Aurion Biotech IPO Registration Document (S-1)
Aurion Biotech has filed to go public with an IPO on the New York Stock Exchange (NYSE).